Current Atherosclerosis Reports

, Volume 6, Issue 5, pp 333–334 | Cite as

Clinical trials report

  • Peter P. Toth
Article
  • 17 Downloads

Keywords

Reverse Cholesterol Transport Plaque Volume Atheromatous Plaque Acute Coronary Event Cholesterol Ester Transfer Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Toth PP: Clinician update: HDL and cardiovascular risk. Circulation 2004, 109: 1809–1812.PubMedCrossRefGoogle Scholar
  2. 2.
    Gotto AM, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. A working group report and update. J Am Coll Cardiol 2004, 43: 717–724.PubMedCrossRefGoogle Scholar
  3. 3.
    Toth PP: Reverse cholesterol transport: high-density lipoprotein’s magnificent mile. Curr Atheroscler Rep 2003, 5: 386–393.PubMedGoogle Scholar
  4. 4.
    Nofer J, Kegrel B, Fobker M, et al.: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161: 1–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Toth PP, Davidson MH: Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol 2004, 19: 374–379.PubMedCrossRefGoogle Scholar
  6. 6.
    Robins SJ, Collins D, Wittes JT, et al.: VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001, 285: 1586–1589.CrossRefGoogle Scholar
  7. 7.
    Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279: 1615–1622.PubMedCrossRefGoogle Scholar
  8. 8.
    Assman G: Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 2000, 87(suppl): 2B-7B.Google Scholar
  9. 9.
    Miyazak A, Sakuma S, Morikawa W, et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioslcer Thromb Vasc Biol 1995, 15: 1882–1888.Google Scholar
  10. 10.
    Tangirala RK, Tsukamoto K, Chun SH, et al.: Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999, 100: 1816–1822.PubMedGoogle Scholar
  11. 11.
    Weisgraber KH, Rall SC, Bersot TP, et al.: Apolipoprotein A-I Milano: detection of normal A-I in affected subjects and evidence for cysteine to arginine substitution in the variant A-I. J Biol Chem 1983, 258: 2508–2513.PubMedGoogle Scholar
  12. 12.
    Chiesa G, Sirtori CR: Apolipoprotein A-I Milano: current perspectives. Curr Opin Lipidol 2003, 14: 159–163.PubMedCrossRefGoogle Scholar
  13. 13.
    Chisea G, Monteggia E, Marchesi M, et al.: Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90: 974–980.CrossRefGoogle Scholar
  14. 14.
    Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001, 103: 3047–3050.PubMedGoogle Scholar
  15. 15.
    Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105: 290–292.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Peter P. Toth

There are no affiliations available

Personalised recommendations